Intrabio
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 W 5th St Ste 1100, Austin, Texas, 78...Website
www.intrabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Intrabio
IntraBio is a leader in discovering, developing, and commercializing novel therapies for rare and neurodegenerative diseases with high unmet medical needs. The company focuses on innovative drug development, particularly their lead program IB1001, which is an orally administered modified amino acid aimed at treating Niemann-Pick Disease Type C. IntraBio's team is dedicated to translating research into potential treatments that significantly improve the lives of patients and their families. They actively publish clinical study results in leading medical journals to share advancements in their therapeutic approaches.Explore more
Intrabio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Intrabio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Intrabio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Intrabio recently announced quarterly report
Check out if Intrabio is spiking on competitors!
Intrabio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Intrabio
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Intrabio has new funding data
Click to see if Intrabio had a recent Job posting/layoffs
Product Launch: Get notified when Intrabio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Intrabio
Find 3 more new buyers
Compare Similar Companies to Intrabio
Compare insights from companies similar to Intrabio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Intrabio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Intrabio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Intrabio.
Intrabio Tech Stack
A closer look at the technologies used by Intrabio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
Intrabio News & Media
IntraBio wins EC approval of Aqneursa | The Pharmaletter
Texas, USA-based IntraBio revealed that the European Commission granted marketing authorization to Aqneursa (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) disease, following a positive opinion from the European Medicines Agency (EMA) human medicines committee, CHMP.IntraBio Inc. Completes Recruitment for IB1001 A-T Pivotal Clinical Trial
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. announced today that it has completed recruitment for its Phase III Pivotal Trial “IB1001-303”, Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A randomized, placebo-controlled, double-blind, crossover study (NCT06673056). Enrollment for the Phase III trial commenced in May 2025 and was conducted across ten multinational trial sites in Germany, Slovakia, Spain, Switzerland, the United Kingdom, and the United States. After four weeks, 1IntraBio Announces U.S. FDA Approval of AQNEURSA for the Treatment of Niemann-Pick Disease Type C
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc., a leader in the discovery and development of innovative drugs for rare neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. AQNEURSA is the only FDA-approved stand-alone therapy indicated for the treatment of NPC. "IntraBio has been dNiemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health
The expected launch of various emerging therapies shall fuel the growth of the Niemann-Pick disease type C market during the forecast period, i.e., 2023–2032. The Niemann-Pick disease type C market size is expected to increase at a significant CAGR LAS VEGAS, Sept. 19, 2023 /PRNewswire/...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Intrabio
Sign Up For FreeTo access detailed company insights
IntraBio is a leader in discovering, developing, and commercializing novel therapies for rare and neurodegenerative diseases with high unmet medical needs. The company focuses on innovative drug development, particularly their lead program IB1001, which is an orally administered modified amino acid aimed at treating Niemann-Pick Disease Type C. Int... Read More
